The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
about
Linking multiple pathogenic pathways in Alzheimer's diseaseManagement of Venous Thromboembolism: Recent Advances in Oral Anticoagulation TherapyMonitoring anticoagulant therapy with new oral agentsCritical appraisal of dabigatran in the treatment of deep vein thrombosis and pulmonary embolismReversal of oral anticoagulationThe use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgeryAtrial fibrillation: a review of recent studies with a focus on those from the duke clinical research instituteReversal of target-specific oral anticoagulantsSafety of new oral anticoagulant drugs: a perspectiveNo influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic strokeNew oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic eventsNon-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused ReviewLiver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting systemAn update on recent patents on thrombin inhibitors (2010 - 2013)Drug-induced liver injury: Towards early prediction and risk stratificationNew synthetic thrombin inhibitors: molecular design and experimental verificationPharmacometric characterization of dabigatran hemodialysisA novel μ-fluidic whole blood coagulation assay based on Rayleigh surface-acoustic waves as a point-of-care method to detect anticoagulantsDabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.Direct thrombin inhibitors.New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome.Hemorrhagic complications associated with dabigatran use.Trends in the development of oral anticoagulants.Management of anticoagulant-related intracranial hemorrhage: an evidence-based review.Management of gastrointestinal bleeding in patients anticoagulated with dabigatran compared with warfarin: a retrospective, comparative case review.Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C.Frequency and predictors of bleeding complications associated with anti-coagulant therapy using dabigatran in Japanese patients with atrial fibrillationNew options with dabigatran etexilate in anticoagulant therapyNew oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplastyLaboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.Management of non-vitamin K antagonist oral anticoagulants in the perioperative settingOral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Reversal of novel oral anticoagulants in patients with major bleeding.Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants.A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin timeCoagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatranPharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism.BJCP 40th anniversary: moving forward, looking back.Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.
P2860
Q26746112-2646035A-BAFA-44C1-BE3E-6128BDF640D1Q26766303-5F5B0B8A-AD46-4DE4-832E-0184FFDDCB54Q26771728-AEFC4770-DC12-4AF2-ACC9-84D72467705AQ26799691-3F78C562-5B64-4B56-B683-148F6230EF9FQ26827835-687DDDED-8386-456D-817C-5A467F4E3C9DQ26828439-876CE47D-C9D2-4BE3-B5C1-F20329D4D18CQ26851235-96672CFE-4685-4978-B90B-B05B4A08E6AAQ27003866-D66AA33F-A431-4EB5-9009-3E4EC5FDB316Q27016072-3EE27EC8-68BC-4BB5-814C-0296E4153B8FQ27334041-C883674D-BDCB-42AF-BBD7-B1051385F5E7Q28080616-473EA74E-C8C4-4611-A8C7-8A101C039F31Q28081918-1CC29BE2-B7FF-4AA1-8660-656EB2E1984EQ28257188-D2502070-569B-4466-AEB9-19EC8C3947B7Q28299898-19ED3FC0-0E49-41F3-A273-3C30D84EB405Q28468389-916536EE-7BA4-417E-AADD-B07CD631A216Q28744536-8D0B6700-AD88-49C1-9B2F-39D51B6DB824Q29584461-A6770B33-B93A-4D32-ADC1-A8099C3001B4Q30429127-474386D3-522E-4ABC-932F-E4E3C86B3178Q33381801-38DCA112-1AEA-425B-9B2F-93459EA13782Q33393692-7AFFF576-94A2-4144-8D91-59B6FF34EE52Q33397359-EF3DB374-36A5-4043-9B81-8667E9962333Q33403265-ABEFABDB-C14D-4E65-B907-19F088C60461Q33424198-F9949426-5E58-45E8-8190-EE35494E40A1Q33750215-64AFCE9B-8C5E-42F9-80AE-D719AC5B9822Q33803111-98DC74AD-E7B8-478E-9C2C-336B684DF620Q33804810-DE4D2E7E-493E-4A86-B69D-074613F28420Q33847039-6EA71DCF-979A-4ED3-842A-DCF8FC4DCDACQ33888320-1301A742-7821-463B-AFED-09C82251457EQ33891915-FFEE6BAF-E292-40D6-BDA8-FB3BFF56BF9AQ34206252-902ABC8A-2986-4F33-B26C-A6A2E2A65309Q34207558-A1D21515-1739-4E90-96B4-29CFE4CFB4ADQ34252907-CD35A557-5D99-4269-B987-52758B288585Q34326655-0735896F-7DBD-4E28-9745-D8FCE4B0FFBEQ34469002-0A2804CC-CD22-41A9-824C-E1BC6C2CC11DQ34571082-3E5FC988-5C48-4FBB-A7F4-0929B62C13ADQ34571099-3B306F2A-A080-4528-8BA8-47D3A27A8935Q34611004-42EBA670-849A-4BC7-A9D1-BA4B3784CF1DQ34627780-47367CA5-F597-4FAB-8A1B-7CFD26274C29Q34635476-822EFF15-9725-486A-AAAB-3CB770F22873Q34638063-817B6089-38C6-4913-9659-E4F4AD15F5F0
P2860
The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The pharmacokinetics, pharmaco ...... tor, in healthy male subjects.
@en
type
label
The pharmacokinetics, pharmaco ...... tor, in healthy male subjects.
@en
prefLabel
The pharmacokinetics, pharmaco ...... tor, in healthy male subjects.
@en
P2093
P2860
P1476
The pharmacokinetics, pharmaco ...... tor, in healthy male subjects.
@en
P2093
Dietmar Gansser
Hildegard Stähle
Joachim Stangier
Karin Rathgen
Willy Roth
P2860
P304
P356
10.1111/J.1365-2125.2007.02899.X
P407
P577
2007-05-15T00:00:00Z